FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 90 filers reported holding FATE THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 0.63 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $997,000 | +23.5% | 64,186 | +61.4% | 0.05% | +20.9% |
| Q2 2019 | $807,000 | +15.5% | 39,770 | 0.0% | 0.04% | +19.4% |
| Q1 2019 | $699,000 | -13.9% | 39,770 | -37.2% | 0.04% | -23.4% |
| Q4 2018 | $812,000 | -12.2% | 63,325 | +11.6% | 0.05% | +17.5% |
| Q3 2018 | $925,000 | +40.6% | 56,760 | -2.2% | 0.04% | +150.0% |
| Q2 2018 | $658,000 | +31.1% | 58,030 | +12.8% | 0.02% | +23.1% |
| Q1 2018 | $502,000 | – | 51,460 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
| Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
| Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
| DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
| Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
| Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
| Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
| Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
| Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |